The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Coxsackievirus A21 on Mouse Models of Colorectal Cancer
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Cancer is a major cause of death worldwide. Colorectal cancer is the second most common type. Additional treatments like chemotherapy and radiation therapy may be recommended. Developing new techniques is vital due to drug resistance and a lack of targeted therapies.
OBJECTIVE: In this study, the effects of mesenchymal stem cells (MSCs) loaded with oncolytic Coxsackievirus A21 (CVA21) on a mouse model of CRC were investigated.
METHODS: The therapeutic potency of MSCs loaded with oncolytic CVA21 was evaluated in an experimental mouse model of colorectal cancer which received an injection CT26 cells per mouse subcutaneously. Splenocyte proliferation index, lactate dehydrogenase (LDH) assay, nitric oxide (NO) production assessment, and cytokine assay (IFN-γ, IL-4, IL-10, and TGF-β) in the splenocyte supernatant were all used to evaluate the impact of MSCs loaded with CVA21.
RESULTS: The results of this study showed that the treatment of a mouse model of colorectal cancer with MSCs loaded with oncolytic CVA21 could significantly suppress the tumor growth, which was accompanied by stimulation of splenocytes proliferation index, an increase of NO and LDH. Also, MSCs loaded with oncolytic CVA21 increased the secretion of IFN-γ and decreased the secretion of IL-4, IL-10, and TGF-β.
CONCLUSION: The results of the current study suggest that MSCs loaded with oncolytic CVA21 therapy for the CRC mouse model may have some potential advantages. On the other hand, the results of the study showed that, in addition to activating the acquired immune system, the use of MSCs loaded with oncolytic CVA21 also stimulates the innate immune system by increasing levels of nitric oxide.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current cancer drug targets - (2024) vom: 24. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karbalaee, Reza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-tumor immunity |
|---|
| Anmerkungen: |
Date Revised 04.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0115680096273465231201115839 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367999471 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367999471 | ||
| 003 | DE-627 | ||
| 005 | 20240204232051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240204s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115680096273465231201115839 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1280.xml |
| 035 | |a (DE-627)NLM367999471 | ||
| 035 | |a (NLM)38310465 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karbalaee, Reza |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Coxsackievirus A21 on Mouse Models of Colorectal Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Cancer is a major cause of death worldwide. Colorectal cancer is the second most common type. Additional treatments like chemotherapy and radiation therapy may be recommended. Developing new techniques is vital due to drug resistance and a lack of targeted therapies | ||
| 520 | |a OBJECTIVE: In this study, the effects of mesenchymal stem cells (MSCs) loaded with oncolytic Coxsackievirus A21 (CVA21) on a mouse model of CRC were investigated | ||
| 520 | |a METHODS: The therapeutic potency of MSCs loaded with oncolytic CVA21 was evaluated in an experimental mouse model of colorectal cancer which received an injection CT26 cells per mouse subcutaneously. Splenocyte proliferation index, lactate dehydrogenase (LDH) assay, nitric oxide (NO) production assessment, and cytokine assay (IFN-γ, IL-4, IL-10, and TGF-β) in the splenocyte supernatant were all used to evaluate the impact of MSCs loaded with CVA21 | ||
| 520 | |a RESULTS: The results of this study showed that the treatment of a mouse model of colorectal cancer with MSCs loaded with oncolytic CVA21 could significantly suppress the tumor growth, which was accompanied by stimulation of splenocytes proliferation index, an increase of NO and LDH. Also, MSCs loaded with oncolytic CVA21 increased the secretion of IFN-γ and decreased the secretion of IL-4, IL-10, and TGF-β | ||
| 520 | |a CONCLUSION: The results of the current study suggest that MSCs loaded with oncolytic CVA21 therapy for the CRC mouse model may have some potential advantages. On the other hand, the results of the study showed that, in addition to activating the acquired immune system, the use of MSCs loaded with oncolytic CVA21 also stimulates the innate immune system by increasing levels of nitric oxide | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-tumor immunity | |
| 650 | 4 | |a CT26 cell line | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Coxsackievirus A21 | |
| 650 | 4 | |a Mesenchymal stem cells | |
| 650 | 4 | |a Mouse model | |
| 650 | 4 | |a Oncolytic virus. | |
| 700 | 1 | |a Mehdizadeh, Saber |e verfasserin |4 aut | |
| 700 | 1 | |a Ghaleh, Hadi Esmaeili Gouvarchin |e verfasserin |4 aut | |
| 700 | 1 | |a Izadi, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Kondori, Bahman Jalali |e verfasserin |4 aut | |
| 700 | 1 | |a Dorostkar, Ruhollah |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Seyed Morteza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g (2024) vom: 24. Jan. |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:24 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115680096273465231201115839 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 24 |c 01 | ||